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Introduction 
 
Alexander Kelle 
 
 
Historically, the possibilities of waging chemical and biological warfare have been 
dependent on the state of scientific and technological knowledge in chemistry and biology. 
To illustrate this point with respect to developments in chemistry, it was a particular aspect 
of the industrial revolution which made chemical warfare during World War I possible 
(Aftalion: 2001, 32ff.). As Robinson points out, the “technology initially responsible” for 
bringing “toxic weapons out from their prehistory” was the “large-scale liquefaction of 
chlorine gas and its packaging into pressure cylinders” (Robinson: 1998, 18). In the inter-
war period civilian research into a new group of organophosphorous compounds in the 
context of work on plastic additives and fertilizers first led to the development and 
production of the first nerve agent, Tabun in December 1936. This discovery was followed 
by the synthesis of Sarin in 1939 and Soman in 1944 (Martinetz: 1995). After World War 
II civilian work to exploit the new group of toxic organophosphates continued, leading to 
the development of even more toxic compounds. One of these super-toxic compounds was 
adopted by the US military and became known as the VX chemical warfare agent during 
the 1950s (SIPRI: 1971, 71ff.). 
Similarly, as Dando has demonstrated for the “three generations of offensive 
biological warfare programs” of the 20th century, all the military programs were 
“developing on the back of growth in scientific knowledge.” (Dando: 1999, 51) He points 
out that military BW programs exploited scientific discoveries in the areas of (1) 
bacteriology, paving the way for the BW-based sabotage activities during World War I 
(Wheelis: 1999), (2) aerobiology, providing for the knowledge to spread BW agents over 
large geographic areas, and thereby giving also non-contagious agents their potential to be 
used as mass casualty weapons, and (3) the beginning biotechnology revolution, which was 
utilized in the BW program of the former Soviet Union. According to one account, Soviet 
BW-scientists worked on genetically modified pathogens, including “antibiotic-resistant 
strains of plague, anthrax, tularemia, and glanders.” (Tucker: 1999, 2) 
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States parties to the Biological Weapons Convention (BWC) have acknowledged the 
changing S&T basis of the BW proliferation problem in successive quinquennial review 
conferences, beginning in 1980. While the initial review document statement concerning 
S&T advances was a rather concise one, BWC states parties since then have seen the need 
to add more and more developments of relevance to the Convention to the respective 
paragraphs of the final declarations (Kelle/Nixdorff/Dando: 2006, 43ff.). During the 
Review Conference’s Preparatory Committee meeting in April 2006 BWC states parties 
agreed to have included among the background documents to be prepared for the 
Conference one on  
“new scientific and technological developments relevant to the Convention, to be 
compiled from information submitted by States Parties as well as from information 
provided by relevant international organisations” (Preparatory Committee for the 6th 
BWC Review Conference: 2006, 4). 
Nine BWC states parties – Argentina, Australia, Czech Republic, Netherlands, Portugal, 
Russian Federation, Sweden, United Kingdom, and United States – followed this call and 
submitted such information to the Review Conference Secretariat, which in turn has 
produced the requested background document (Secretariat of the 6th BWC Review 
Conference: 2006). This document discusses “significant developments” in the areas of 
“biotechnology; genomics; proteomics; bioinformatics and computational biology; systems 
biology; drug discovery, design and delivery; synthetic biology and biological engineering; 
as well as a number of other relevant developments”, such as for example nanotechnology. 
The 6th BWC Review Conference, however, which was held in Geneva from 20 November 
to 8 December 2006 broke with tradition and introduced for the first time a catch-all 
clause, when in its final declaration no specific new areas of concern are mentioned. 
Instead, the section on Article I states that “[t]he Conference reaffirms that Article I applies 
to all scientific and technological developments in the life sciences and in other fields of 
science relevant to the Convention.” (emphasis added; 6th BWC Review Conference: 2006, 
10) Unfortunately, this reaffirmation of the comprehensive character of the BWC in 
relation to S&T advances has not been supported by the establishment of a scientific 
advisory panel, which some had advocated in the months before the Review Conference. 
Only a small Implementation Support Unit whose tasks are limited to administrative 
support and improved implementation of Confidence Building Measures has been set up 
by the Conference. Equally unsatisfactory is the absence of S&T developments from the 
list of topics to be addressed during the new intersessional process from 2007 to 2010. In 
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addition, as Pearson has pointed out, “an appeal [contained in the 1996 Final Declaration, 
AK] to ‘scientific communities to lend their support only to activities that have 
justification for prophylactic, protective and other peaceful purposes, and [to] refrain from 
undertaking or supporting activities which are in breach of the obligations deriving from 
provisions of the Convention’ has inexplicably been removed” (Pearson: 11 December 
2006) from the 2006 Final Declaration. Thus, states parties to the BWC have neither given 
themselves the organisational structure nor allocated a specific time for reviewing S&T 
advances between now and the 7th Review Conference in 2011. They have also weakened 
the normative framework that can serve as guidance for life scientists’ actions. Revisiting 
the issue of codes of conducts as one of the topics to be discussed in 2008 does hardly 
make up for these omissions.  
 
Similar to the BW control regime, the drafters of the Chemical Weapons Convention 
(CWC) anticipated changes in science and technology (S&T) and the chemical industry, 
which is to be inspected under the CWC’s industry verification regime. The CWC contains 
a review mechanism and the Director General of the organisation created to oversee the 
CWC’s implementation – the Organisation for the Prohibition of Chemical Weapons 
(OPCW) – has been tasked to set up a Scientific Advisory Board (SAB) to advise him on 
S&T matters of relevance to the CWC. More specifically, the Review Conferences of the 
CWC, the first of which took place in April/May 2003 and the second of which is 
scheduled for 2008, are mandated to “take into account any relevant scientific and 
technological developments.” (CWC Article VIII, para 22) In order to do this, the First 
Review Conference had before it a report by the SAB, addressing a number of S&T areas, 
most of which were directly related to the day-to-day operation of the CWC. (OPCW: 
2003) A farther reaching review of S&T advances was not conducted during the First 
CWC Review Conference. What has so far become known about preparations for the 
Second CWC Review Conference to be held in spring 2008, the pattern of the first review 
process is likely to be repeated. As in the run-up to the first Review an open-ended 
working group has been set up to prepare the Second Review Conference and the SAB has 
again started to look into new S&T developments of relevance to the CWC. A meeting to 
this end involving the International Union of Pure and Applied Chemistry (IUPAC) is 
scheduled to take place in April 2007 in Croatia.  
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What is noteworthy in this context is the increasing overlap of areas of concern for both the 
BW and the CW control regimes. The chemistry of the 21st century is a far cry from the 
one of the 1980s, which guided negotiations for the CWC verification regime. The new 
chemistry is utilizing other scientific disciplines and technologies to a much higher degree 
in its quest for new chemical compounds. Especially in the area of drug development and 
delivery, scientific and technological advances in biotechnology and genomics, robotics 
(Vogt: 2002), information technology (Holland and Mitchell: 1999; Ritchie: 2001; Azuaje: 
2006 in this volume), and nanotechnology (Davis: 1997; Sahoo and Labhasetwar: 2002; 
Byrne: 2006 in this volume) act as enablers of combinatorial chemistry and high 
throughput screening, which in turn have become key tools in pharmaceutical research and 
development (Wood and Scott: 2000; Wheelis: 2002). 
Seen in a wider perspective, it has been acknowledged that we are witnessing a 
“multidisciplinary technology revolution” (RAND: 2001), what is often overlooked is the 
fact that many of the products flowing from the biotechnology revolution that will impact 
on life processes at various levels are basically chemical compounds. All chemical 
compounds, however, which through their toxic properties could harm man, fall under the 
prohibitions of the CWC. Some key areas of the revolution in the life sciences threaten to 
expand not only the range of toxic chemicals that could be misused for malign purposes 
but also our knowledge of the targets of potentially harmful biologically active chemical 
substances in the human body. In decades to come, this can be expected to shift the “focus 
of the proliferation problem from the chemical or biological warfare agent as object of 
malign manipulation to the physiological target in the human body as the object of attack.” 
(Kelle/Nixdorff/Dando: 2006, 4) Given a plethora of research activities over the last 
decade, such targets in the nervous, immune and neuro-endocrine immune systems today 
are much better understood and thus more susceptible to potential misuse. As an NAS 
study on Globalization, Biosecurity and the Future of the Life Sciences has pointed out 
with reference to microbial threats: 
“While [the] greater awareness of host defense may lead to new strategies for the 
recognition, prevention, treatment, and prediction of outcome of microbial disease, it 
also broadens the knowledge base from which bioterrorists could design new forms of 
biological weapons that disrupt host homeostatic systems, … with diverse and 
potentially devastating consequences.” (NAS: 2006, 37)  
The fact that this “paradigm shift is fuelled by the decoding of the human genome and 
finds its expression in the establishment of new scientific subfields such as systems 
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biology” (Kelle/Nixdorff/Dando: 2006, 3) leads us back to the various enabling 
technologies that feed into drug design and development. 
 
At a very general level the genomics and proteomics revolution equals, to use Piers 
Millett’s terms, the discovery of the “dictionaries and thesauri of biology” (Millett: 2007, 
in this volume). However, already in the year 2000 one survey has cautioned against a 
“definition creep and the changing meaning of genomics” (Cooke-Degan et.al.: 2000) in 
the reviewed literature. The sub-differentiation of genomics into various subfields becomes 
evident in another summary, according to which genomic technologies involve “DNA 
synthesis, sequencing, genotyping, and expression profiling” but also  
“proteomics (peptide synthesis, protein sequencing, and mass spectrometry), and 
imaging. Innovative technologies might include applications of nanobiotechnology, 
isolation, imaging, and characterization of single molecules.” (Cornell Genomics 
Initiative, 2001) 
To take just one example of the technologies mentioned in this quote, DNA synthesis has 
over the past few years allowed for the construction of ever longer DNA sequences 
resulting in the de novo synthesis of the Poliovirus in 2002 (Cello: 2002). The possibility to 
apply such a technology for both benevolent and malevolent purposes, i.e. its dual-use 
potential, is obvious. Even the resurrection of extinct viruses like the 1918 Spanish flu 
virus is within the realm of the possible, once the genome of a particular virus has been 
deciphered. 
Although the exact meaning of another term – post-genomics – is still contested, 
there seems to be general agreement that we live in the post-genomic era. Whether the term 
is meant to refer to an increasing emphasis on functional genomics (see Millett, in this 
volume) or to “anything connected with teasing higher biological meaning and function out 
of raw sequence data” (Science Online: 2006), there seems to be a general recognition that 
key tasks in this new era encompass the storage, retrieval, analysis, and integration of 
biological data. This is the domain of bioinformatics. As Francisco Azuaje in his 
contribution to this volume outlines, this area has moved away from the analysis of single 
genes and genomes to the complex computational modelling of networks in order to enable 
the discovery of new drug targets, and the development of new medicines or diagnostic 
tools. One continuous challenge in this area remains the integration of data from diverse 
sources and in various formats. (Searls: 2000; Fellenberg: 2003) 
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Just like bioinformatics, nanotechnology (NT) has over the past decade seen a dramatic 
increase in research output, funding and recognition as a crucial area of interdisciplinary 
collaboration involving at least microbiology, bioinformatics, medicine and materials 
science. Both the integrative dimension as well as the differentiation into several nano-
subdisciplines is reflected in the growing number and specialisation of NT-related 
academic journals. Not only is the number of journals that cover NT across the board 
increasing – with Nature Nanotechnology being one of the more recent additions to the 
field – the increasing degree of specificity in coverage of some journals is evident as well. 
Of greatest relevance here are titles like Nanomedicine, Journal of Biomedical 
Nanotechnology, and Nanotoxicology. The latter journal’s mission statement contains a 
commitment to publish research on “the potential for human and environmental exposure, 
hazard and risk associated with the use and development of nano-structured materials.“ As 
Oberdörster and colleagues point out, nanotoxicology has its roots in studies on ultrafine 
particles, which have surrounded humans “throughout their evolutionary stages” (2005: 
823). Seen from this perspective, nanotechnology is adding just another dimension to the 
challenge of risk assessment of nanoparticles. While such a risk assessment would address 
the negative side-effects of nano-engineered materials, it would in all likelihood not cover 
the dual use dimension of this area of research, i.e. its deliberate misuse for malign 
purposes. Concerning the dual use potential of nanotechnology an international workshop 
of the US National Academy of Sciences concluded that because the “technology is 
expected to make for relatively inexpensive, small scale science, the dual-use risks will be 
similar to those of more conventional biotechnology in terms of ease of access and 
detection” (NAS: 2005, 66), i.e. access will be easy, given the to be expected wide-spread 
diffusion of the technology and, correspondingly, detection of misuse will be difficult, 
especially given the restrictions of current control mechanisms. 
 On a different scale than nanoscience and nanotechnology are micro reactors, 
whose development has made great progress in recent years. Development of micro 
reactors is likely to have a more immediate impact on chemical production technology than 
the other S&T developments discussed so far. As Watts explains: 
“Reactions performed in a micro reactor invariably generate comparatively pure 
products in high yield, when compared to the equivalent bulk reactions, in much 
shorter times.” (Watts: 2007, in this volume) 
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These characteristics, combined with the possibility to run micro reactors in parallel and 
thereby scale up the production volume that can be achieved with these devices, can lead to 
production capacities that might pose a proliferation problem and that also fall under the 
declaration requirements of the CWC. It is therefore to be welcomed that the OPCW SAB 
has been tasked to analyse the potential implications of micro reactors for the CWC. This 
emphasis on micro reactors – but also on nanotechnology – was re-confirmed by the 
OPCW Director General, Ambassador Rogelio Pfirter, in his address to the 11th Session of 
the Conference of States Parties to the OPCW (OPCW: 2006, 12).  
 
Yet, no matter how well the SAB or other groups perform assessments of S&T 
developments that are of relevance to the chemical or biological weapons proliferation 
problem and corresponding efforts to prevent the spread of such weapons, in the final 
analysis responsibility to act on such assessments and concomitant recommendations rests 
with the states parties to the two regimes collectively and on states individually. As a first 
step, it would be a great improvement if more states were to actively engage in such a 
technology assessment in the first place. As mentioned above, only nine states parties to 
the BWC contributed material to a background document on S&T issues for the 6th BWC 
Review Conference last year. Although there may be a geographical concentration in some 
areas of cutting edge research described in this report, it is difficult to imagine that less 
than a dozen states have a stake in the potential regulation of such new areas like DNA 
synthesis, bioinformatics, nanotechnology, drug development, or micro reactors. 
 The contributions that follow were commissioned for a workshop that brought 
together life scientists with CBW arms control and nonproliferation experts. As a result, 
one of the tasks for the contributors was to provide an overview of their respective areas of 
expertise in such a way that it would be more easily digestible for non-experts. It is hoped 
that this approach will make the contributions to this volume of interest to a wider 
audience. Those wishing to delve deeper into one or more of the areas covered might find 
the references provided at the end a useful starting point. 
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Genomics and Proteomics 
 
Piers D Millett 
 
 
Introduction 
Dictionaries are like watches; the worst is better than none, and the best 
cannot be expected to go quite true. ~ Samuel Johnson 
 
In many ways, genomics and proteomics are the dictionaries and thesauri of biology. The 
databases which house the information generated by the two disciplines contain 
descriptions and functions of the ‘words’ of life. The biological alphabet may consist of 
only four letters but this by no means seems to limit the diversity of both form and 
function. This paper briefly reviews the current status of these two rapidly developing 
fields and discusses their potential for finding non-peaceful applications. 
 
Genomics 
The life sciences have witnessed many important events over the last couple of decades, 
not least of which is the advent of genomics. Lockhart et al have noted that: 
…the massive increase in the amount of DNA sequence information and the 
development of technologies to exploit its use… [have prompted] new types of 
experiments… observations, analyses and discoveries… on an unprecedented 
scale…Unfortunately, the billions of bases of DNA sequence do not tell us what all 
the genes do, how cells work, how cells form organisms, what goes wrong in disease, 
how we age or how to develop a drug… The purpose of genomics is to understand 
biology not simply to identify its component parts. (Lockhart and Winzeler: 2000). 
Four interlinked areas of interest have emerged from these efforts: genome mapping and 
sequencing to locate genes on the chromosomes (Boguski and Schuler: 1995) and 
determining the exact order of the nucleotides that make up the DNA of the chromosomes 
(International Human Genome Sequencing Consortium: 2001); structural genomics to 
provide… [a] model structure for all of the tractable macromolecules that are encoded by 
complete genomes (Bremner: 2001); functional genomics to flesh out the relationships 
between genes and phenotypes (White: 2001); and comparative genomics to identify 
functional sequences by comparing various genomes (Bofelli, Nobrega and Rubin: 2004). 
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Genome Mapping and Sequencing 
There are two general types of map – genetic maps and physical maps. Genetic maps 
locate genes in relation to genetic markers, often restriction fragment length 
polymorphisms (RFLPs), variable number of tandem repeat polymorphisms (VNTRs), 
Microsatellite polymorphisms, or single nucleotide polymorphisms (SNPs). Genetic maps 
can be used to create the scaffold for more detailed physical maps. Physical maps order 
clones and/or landmarks to isolate and position genes. This facilitates the study of genome 
organisation and evolution and forms a useful framework for genome sequencing. Three 
types of physical map are commonly used: radiation hybrid maps (landmark-only maps) 
(Cox et al: 1990); clone–based maps (Birren, Mancino and Shizuya: 1999); and sequence-
ready contiguous maps (Marra et al: 1997) (Gregory et al: 1997).   
 
 
FIGURE 1: A Brief History of DNA Sequencing. (Messing and Llaca: 1998) 
 
Once mapped, genes can be sequenced by identifying the order of their nucleotides. As of 
22 August 2005, the three international depositories of gene sequence information (EMBL 
Data Library of the European Molecular Biology Laboratory et al) reported having passed 
100 gigabases of sequence from 165,000 organisms (Anon (online): 2005). Of particular 
importance were the publication of the first eukaryotic genome (a yeast) in 1997 (Clayton 
et al: 1997), the first animal genome (a worm) in 1998 (The C.elegans Sequencing 
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Consortium: 1998), and the human genome (Venter et al: 2001; Lander et al: 2001) in 
2001.  
An overview of key events in the development of the technology to enable these 
reakthroughs can be found in Figure 1. Currently the most utilised methodology is 
ncing (Wilson and Mardis: 1999). 
information gained provides details of molecular function and 
oes not usually confer a detailed understanding of its cellular role. For this more systemic 
y.  
ar note are: interfering with gene function (Figure 2); 
gene-e
ibility of elucidating the genetic variants for complex traits.  Due to its 
stemic approach and the technologies it uses, functional genomics is closely related to 
systems biology. 
 
b
fluorescent DNA seque
 
Structural Genomics 
One approach to attempt to contextualise genes is to examine the structure of its product. 
This offers insights into its function. Relationships between genes, which are difficult to 
obtain through sequence analysis, can be more readily characterised because structural 
traits are better conserved over time. Structural genomics, which is closely related to 
proteomics, takes advantage of many of the same tools as traditional structural biology but 
has developed a different motivation, automation and scale (Bremner: 2001). 
Unfortunately much of the 
d
approaches are necessar
 
Functional Genomics 
Functional genomics contextualises genes by adopting such a systemic approach - focusing 
on all the genes in a genome rather than characterising a single gene at a time. Three areas 
of functional genomics of particul
xpression profiling (Hughes et al: 2000); and genetic mapping of quantitative trait 
loci (Van Eerdewegh et al: 2002). 
Core questions which functional genomics attempts to answer include when is a 
gene expressed, where is its product localized, with which other gene products does it 
interact and what phenotype results if a gene is mutated (Steinmetz and Davis: 2004). This 
provides the poss
sy
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TARGETED DELETION BY 
HOMOLOGOUS 
RECOMBINATION 
INSERTIONAL MUTAGENESIS RNA INTERFERENCE 
Precise gene deletion can be 
readily achieved by homologous 
recombination in yeast and 
mouse. Because this approach 
removes the targeted gene, 
functional reduction is 
complete. In organisms in which 
it works, this method is the gold 
standard. Unfortunately, 
homologous recombination does 
not work efficiently in several 
model organisms, including 
Arabidopsis and Caenorhabditis 
elegans. Although it has been 
shown to work in some cases, as 
seen recently in Drosophila, the 
efficiencies are still too low for 
systematic application. 
Disruption of gene sequences 
can be achieved by insertional 
mutagenesis using transposons 
or other insertion sequences. 
Because the genome insertions 
are random, screening for 
disruption in a gene of interest is 
required. The insertion can lead 
to complete, incomplete or no 
functional reduction, depending 
on where the integration occurs. 
The insertion site and level of 
functional reduction therefore 
need to be determined 
experimentally. The method has 
been used extensively in 
Arabidopsis and Drosophila, 
yeast, mouse and C. elegans. 
RNA interference (RNAi) is the 
newest technology for reducing 
gene expression. It follows 
reports of gene silencing in 
plants and other model 
organisms, and is based on the 
observation from C. elegans that 
adding double-stranded RNA 
(dsRNA) to cells often interferes 
with gene function in a 
sequence-specific manner. In 
most cases, the level of 
functional reduction is 
incomplete and the level of 
specificity is not entirely 
predictable. Nevertheless, RNAi 
has been shown to work in 
many model organisms. Current 
applications are primarily in C. 
elegans, Drosophila, various 
plants, tissue culture cells of 
Drosophila and mammals. 
FIGURE 2: Comparison of Knock-Out Approaches (Adapted from Steinmetz and Davis: 2004). 
 
Comparative Genomics 
By comparing the sequences from different genomes, it is possible to identify areas which 
are conserved and as a result which may be functionally important. There is value in 
comparing species which are closely related (Bofelli et al: November 2004) as well as 
those which are more distant (Bofelli, Nobrega and Rubin: 2004). Using closely related 
species offers the possibility to identify a larger number of functional elements but makes 
them more difficult to identify. Conversely, using species more evolutionary distant 
reduces the number of functional elements they share but makes them easier to identify. 
Being able to extrapolate from simpler, better understood organisms (such as the mouse) 
into more complex ones (such as humans), also has benefits for functional genomics. It has 
also recently become feasible to compare the genomes of different members of a single 
species in an attempt to be able to identify functional sequences which are more species 
specific (Bofelli et al: November 2004). 
Features compared include: sequence similarity, gene location, the length and 
number of exons, the amount of noncoding DNA in each genome, and highly conserved 
regions. This work is, of course, done on computers. The most commonly used tool is 
Basic Local Alignment Search Tool (BLAST) made available by the National Center for 
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Biotechnology Information in the USA. BLAST can be used to infer functional and 
evolutionary relationships between sequences as well as to help identify members of gene 
families. 
 
Proteomics 
Patterson and Aebersold defined proteomics as: 
the systematic study of the many and diverse properties of proteins in a parallel 
manner with the aim of providing detailed descriptions of the structure, function and 
control of biological systems in health and disease (Patterson and Aebersold: 2003).  
Proteins are not only involved in the majority of all biological processes but collectively 
contribute significantly to the understanding of biological systems. Proteomics assesses a 
range of variables, including: sequence; quantity; state of modification; interactions with 
other proteins; activity; and subcellular distribution and structure. 
 
Proteomics – Basic Concepts 
Proteomics evolved from studies of traditional protein chemistry. In combination with 
genomics, protein chemistry provided a link between the observable function of a protein 
and the gene that encoded it (Figure 3). The advent of large repositories of gene sequences 
further facilitated protein identification by allowing correlation of sequences derived 
experimentally through protein chemistry to sequences in the databases. The development 
of genome databases opened the watersheds for this approach. Protein identification was 
now primarily restricted by capacities to extract sequence information from proteins and 
correlate this with the information in the databases. As a result proteomics was dependent 
upon the development of technologies to provide the necessary resources. 
 
 
FIGURE 3: Quantitative Protein Analysis from the Cell to the Identified Protein. (Patterson and Aebersold: 
2003). 
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Proteomics Tools 
Many different technologies have been and are being developed to facilitate proteomics. A 
variety of existing and prototype technologies were described in March 2003 in a 
supplement to Nature Genetics (see Figure 4). 
 
 
FIGURE 4: The Current Status of Proteomic Technologies (Patterson and Aebersold: 2003). 
 
It was the confluence of these and other technologies in the mid-1990s which led to 
creation of proteomics (Figure 5). 
 
FIGURE 5: The Confluence of Divergent Technologies leads to the Advent of Proteomics. 
 
Proteomics Applications 
Speicher asserted that proteomics has an Infinite Potential (Speicher: 2002). Although this 
rather limits what it is and is not possible to do in this section, some thought has been 
given to how the coming of age of this science may impact upon the fight against disease. 
Sam Hanash of the University of Michigan suggests that proteomics will facilitate: 
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“The characterization of submicrobial proteomes (for example, secreted proteins, 
surface proteins and immunogenic proteins) 
Comparative analysis of different strains 
Comparative analysis of different physiological states 
Identification of proteins related to pathogenicity 
Identification of proteins involved in host-pathogen interactions 
Evaluation of mechanisms of action of antimicrobials.”(Hanash: 2003) 
Hanash goes on to provide an example of one successful application of proteomics to 
combating disease. It is asserted that comparative proteomic studies of the parasite 
Plasmodium falciparum have already led to novel drug and vaccine targets.  
 
Potential Malign Applications 
It is possible scientific advances can find detrimental or malign applications in addition to 
those beneficial to humanity. The relationship between science and warfare is well 
documented. In the case of the life sciences, it is possible that they could be used for the 
acquisition or use of chemical, biological or toxin weapons. The prohibition against these 
weapons can be traced back throughout human development. Today, this proscription is 
embodied in the 1972 Biological and Toxin Weapons Convention and the 1993 Chemical 
Weapons Convention. These international instruments, which not only binds the action of 
their member States but also every individual in those States, prohibits the development, 
production, acquisition, transfer, stockpiling and use of chemical, biological or toxin 
weapons. 
The first article of the BWC details part of the scope of this prohibition: 
never in any circumstances to develop, produce, stockpile or otherwise acquire or 
retain:  
(1) Microbial or other biological agents, or toxins whatever their origin or method of 
production, of types and in quantities that have no justification for prophylactic, 
protective or other peaceful purposes;  
(2) Weapons, equipment or means of delivery designed to use such agents or toxins 
for hostile purposes or in armed conflict. (United Nations General Assembly: 1971) 
Similar language exists in the Chemical Weapons Convention. Thus under international 
law, any activity which cannot be justified for prophylactic, protective or other peaceful 
purposes is already prohibited.  
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In practice, scientific research and development in the life sciences has both peaceful and 
malign applications. This creates a nuanced situation, once necessitating a balancing 
between costs and benefits. Some advances will be of more use to anyone wishing to 
acquire or use chemical, biological and toxin weapon. Identifying activities which pose the 
greatest proliferation risk is a difficult issue and one still in the process of being addressed 
(See for Example: The National Academies: 2004). It has been suggested that one 
conceptual starting point for such efforts is to differentiate between directly applicable 
advances and enabling advances (Millett: 2005). Certain developments have a specific 
application which limits their potential utility – such as an ability to influence the 
production of a single hormone. Other developments have a virtually unlimited range of 
application and are innately understood to enable other activities, such as the elucidation of 
a new method of synthetically producing very complex biological samples. Characterising 
advances in this manner allows a very simple cost/benefit analysis to be undertaken – the 
benefits of enabling advances to furthering the aims of science will undoubtedly outweigh 
their proliferation potential. As a result, it has been suggested that enabling advances 
should be exempted from any regime to regulate scientific activity.   
It is clear from the discussions above that both genomics and proteomics are 
enabling advances. The sheer scope of the disciplines and diversity of their applications 
makes it very difficult to discuss their potential malign applications which any specificity. 
However, for illustrative purposes, a recent development is reviewed and a potential 
malign use proposed. 
In the September 2004 edition of the Journal of Biomolecular Screening, Huff et al. 
described a label-free protein screening technology (Huff et al: 2004). It makes use of an 
atomic force microscope to detect proteins and pathogens. The micron-scale tip of the 
atomic force microscope is used to scan and amplify the samples topographical features. 
This allows it to detect molecules bound to proteins by detecting nanometre changes in 
height. In addition, coating the tip with biological molecules provides the opportunity to 
bind specific proteins and can allow measurements of intermolecular binding. The authors 
used this concept to develop a label-free, multiplexed, chip-based detection system that can 
directly determine the amount of virus particles in a sample. 
This tool will have obvious applications in peaceful scientific research – it will 
potentially facilitate the assessment of virus titre in patient samples as well as assisting in 
numerous high-throughput screening processes in modern drug-discovery techniques. It 
would also have potential for both defensive and offensive application in relation to 
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chemical, biological and toxin weapons. In a defensive programme, it could eventually be 
developed into a rapid detection system for chemical, toxin and biological agents. 
Alternatively, in an offensive programme, the same development has the potential to 
facilitate the identification of novel toxins, in developments tests to assess agent 
concentrations, the efficiency of potential countermeasures and progress in attempting to 
counteract them.  
 
Conclusions 
This paper provides a brief overview of the disciplines of genomics and proteomics and 
has asserted that whilst that it is worth noting that they do have potential applications for 
hostile or non-peaceful purposes, due to their overwhelming potential to benefit mankind 
their development should be pursued to the fullest extent possible. It should be noted that 
although every attempt has been made to make this paper as exhaustive as possible, there 
are many additional elements worthy of note, such as a consideration of chip-based micro-
arrays. There is also considerable scope for overlap with other areas under consideration in 
other contributions to this volume, such as systems biology and bioinformatics.  
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From Genes and Genomes to Complex Systems for Supporting 
Knowledge Discovery  
 
Francisco Azuaje 
 
 
This paper provides an overview of some critical, recent advances in bioinformatics, with 
an emphasis on applications and potential implications for the development of systems 
biology.  It also discusses current technological and policy requirements and challenges 
necessary for supporting a more open and integrated international scientific community. 
The study of biological functions and phenomena has shifted from the analysis of 
single biological entities (e.g. genes, proteins) to collections of several thousands of these 
entities interacting via complex information processing networks.   
The area of bioinformatics was traditionally associated with the application of 
information and communication technologies to support molecular biology research.  After 
the completion of several genome sequencing projects it has become a fundamental 
component of the knowledge discovery process. Such a process includes the identification 
of new diagnostic and therapeutic approaches.  In general, bioinformatics currently aims to 
integrate a wider spectrum of technologies and disciplines to support and integrate in 
silico, in vitro and in vivo experimental methodologies and findings.  Bioinformatics is 
constantly evolving with the emergence (or promise) of a systems biology in the post-
genome era.  The expression systems biology is currently used to refer to the integration of 
multiple types of data and information sources, research teams and predictive modelling 
techniques to describe and explain the behaviour of biological systems at different 
organisational and complexity levels. 
Thus, bioinformatics has become a discipline of integration, which is required for 
the development of systems biology: Integration of skills, organisations, data and 
information sources, techniques and analytical views.  Current advances range from the 
description of single genes, small interaction circuits and larger networks of genes and 
proteins.  Such advances require the application of several computational and mathematical 
approaches ranging from probabilistic simulations and relatively complex sets of 
differential equations through simulations of networks in which genes (or proteins) are 
seen as connected switches to larger, higher level dynamic representations of pathways.  
These studies aim to describe the behaviour of genes and proteins over time (e.g. 
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concentrations), dynamic (time-dependent) relationships between relatively small groups 
of genes and proteins, as well as the representation of the flow of information in more 
complex networks of interacting entities and in modular, hierarchical views of specific 
networks.  
Recent advances in bioinformatics have also contributed to the revision of the 
concept of gene or protein function. Thus, biological function may be investigated through 
the definition of networks of biological entities (e.g. genes and proteins) based on 
experimental and computational methods. The inference, analysis and integration of 
networks of genes and gene products are fundamental goals of post-genomic research. 
Over the past few years several data- and knowledge-driven computational approaches 
have been proposed, which have provided relevant insights into the informational 
complexity and function of some of such networks in different organisms. In general, a 
node in such networks represents a biological entity and a link represents a functional 
interaction between a pair of entities (e.g. gene regulation, physical protein-protein 
interaction, etc.).  The mathematical analysis of the resulting networks in different model 
organisms and biological phenomena also provides the basis for understanding important 
functional properties of these systems, e.g. interconnectivity, robustness, evolution, 
specialisation.  This offers new opportunities for detecting potential therapeutic targets, 
understanding evolution and re-engineering systems.  These are fundamental components 
of an “information paradigm” necessary to understand both normal and disease phenomena 
and conditions. 
Borrowing a metaphor from the world of gastronomy: the sequencing of genomes 
may be seen, for example, as the definition of the list of ingredients required to prepare a 
meal. It is not, as the media have commonly argued, the construction of a “blue print” of 
systems or organisms. Systems biology would provide the next steps required to 
understand how and when such “ingredients” should be combined in order to explain or 
manipulate the resulting or desired biological outcomes. Following this metaphor: the 
modelling processes described above would provide different resolutions, levels of details 
or views in the description of the recipes required to understand the function (and 
malfunction) of the systems under study. 
 
In practice, how can bioinformatics exploit pathway network-based knowledge to support 
the development of new drugs, vaccines and diagnostic tools? One of the possible 
approaches comprises the application of comparative genomics principles. Comparative 
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genomics has traditionally aimed at identifying structural (sequence-based) similarities 
between groups of genes or proteins. A network-based approach aims to identify 
fundamental functional and structural features distinguishing, for example, hosts and 
pathogens on the basis of computational representations of their molecular pathways.  One 
major challenge is to detect subtle, but relevant, differences between their functional 
pathways, i.e. networks implementing processes.  This is a complex problem as there are 
significant similarities between human and many pathogens in terms of metabolic 
pathways, for instance.  In the case of infectious diseases a key goal is then to detect 
differences between pathogens, vector organisms and hosts in the hope that such 
differences will highlight potential drug targets (e.g. antibiotics) that will kill the pathogen 
while significantly reducing negative effects on the host (e.g. humans).  Based on this 
assumption, traditional targets have included metabolic pathways and other key networks 
in pathogens that substantially differ from those implemented by humans (Chaudhary and 
Roos, 2005).  For instance, with regard to humans, many parasites have developed 
alternative strategies to synthesise essential proteins. Some parasites (e.g. Leishmania and 
the parasite causing Chagas disease) exhibit metabolic pathways that are not present in 
humans. Many pathogens display significant differences in connection to the metabolism 
of amino acids, others exhibit alternative pathways to compensate for loss of function, and 
others (e.g. the malaria parasite) feed from some of the host’s resources (e.g. haemoglobin) 
to survive.  These differences may point out potential drug targets to fight infections 
(Chaudhary and Roos, 2005).   
Advanced software tools are required to identify and analyse structural and 
functional differences between pathway networks.  In this direction recent research has 
provided promising evidence for the potential of comparative analysis of networks of 
protein interactions relevant to infectious diseases. LaCount and colleagues (2005), for 
instance, experimentally inferred a large-scale version of the network of protein-protein 
interactions of the parasite causing the most severe type of malaria (Plasmodium 
falciparum). They then performed bioinformatics analyses of the topology of this network 
(i.e. connectivity patterns) and other functional properties (e.g. gene co-expression and 
available validated functional annotations for the proteins) to detect groups of proteins 
involved in important processes relevant to this disease (e.g. gene transcription, invasion of 
host cells, etc.). This study reported significant similarities (conserved patterns) of specific 
network regions between P. falciparum and other model organisms, i.e. Saccharomyces 
cerevisiae (baker’s yeast), Drosophila melanogaster (fruit fly), Caenorhabitis elegans 
- 22 - 
(nematode worm) and Helicobacter pylori. The resulting networks comprise dense 
interconnected structures which are significantly shared by yeast and worm. However, 
some of such sub-networks were not detected in P. falciparum. Furthermore, the authors 
provided strong statistical evidence to reject the hypothesis that all such differences were 
mainly caused by noise or experimental bias of the available data.  Another key conclusion 
of this study is that “conservation of specific groups of related genes does not necessarily 
imply conservation of interactions among their encoded proteins” (LaCount et al., 2005).  
These types of findings at least motivate further research on the application of 
computational and mathematical approaches to determine potential network-based drug 
targets. 
Other researchers are currently exploring the possibility of analysing properties 
such as informational robustness of systems to identify potential drug targets or therapeutic 
strategies. For example, it has been suggested that the induction of dormancy in tumour 
cells, instead of trying to eradicate the tumour, may be a clinical strategy for treating 
cancers (Kitano, 2004a).  This may be achieved by detecting architectural, topological and 
dynamic features defining the robustness of a particular biological system to particular 
perturbations. Similar strategies have been proposed for the treatment of the HIV infection 
(Kitano, 2004b). 
The post-genome bioinformatics era is also characterised by and dependent on the 
development of software tools and infrastructures to allow researchers to access, combine 
and analyse geographically- and computationally-distributed information (Global Grid 
Forum, 2005; grid.org, 2005).  Its success will be driven by our capacity to propose and 
promote standards for representing, storing and sharing experimental data and analysis 
results. It will also require the implementation of secure and user-friendly computational 
platforms for multi-disciplinary communities. Such advances will significantly support 
emerging technologies, such as Grid computing, that have the potential to significantly 
accelerate scientific research and drug design. Through Grid computing scientists would be 
able to use a massive virtual computer with the capacity to access multiple resources 
(machines, databases, programs, etc.) in a unified, automated and transparent fashion. 
Other important factors for the development of bioinformatics and systems biology 
are Open Source (OSI, 2005) software and Open Access publishing (Butler, 2004; 
Worlock, 2004).  The former does not only refer to the availability of free software tools 
and access to their source codes, but also it implies other crucial issues relating to software 
distribution terms. For example, an open source license allows modifications to the 
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original software and requires that the distribution of the derived products be done under 
open source terms.  Such licenses should not discriminate people, communities or 
organizations. Moreover, it should not restrict other software products (including close 
source software) that may be used or distributed with the licensed software tool.  Open 
source systems also aim to produce computing platform- and interface-independent 
software. Open access publishing ensures that scientific articles and related contributions 
are freely accessible via the Internet and stored in international open access repositories 
(e.g. www.pubmedcentral.nih.gov). With this publication method the authors grant to any 
user the right to reproduce, use and distribute a research article in any form if there is 
proper attribution of authorship and correct citation, and if there is no introduction of major 
errors to the original information.  Representative examples of open access publishing 
initiatives are: BioMed Central (www.biomedcentral.com) and the Public Library of 
Science (www.plos.org).  The traditional publication industry has also started to explore 
the feasibility of open access. For example, the Oxford Open initiative 
(www.oxfordjournals.org/oxfordopen) currently include full open access to some of the 
Oxford University Press journals (e.g. Nucleic Acids Research) and optional open access 
modalities (e.g. Bioinformatics). 
Open source software and open access publishing may play a fundamental role in 
the promotion of standardized, transparent, integrated and global research and development 
resources.  From ethical and security perspectives, it has been suggested that both open 
source and open access publishing may result in opportunities to foster scrutiny, 
monitoring and a more effective peer-review process of methodologies, systems and 
applications in a more integrated, international environment.  On the other hand, some 
users, policy makers and researchers may suspect that such openness (software source and 
access publishing) and integration (global distributed computing, e.g. Grid technologies) 
may promote the uncontrolled proliferation of technologies, knowledge and materials, 
which may be misused or illegally manipulated (e.g. terrorism).  However, many of us 
believe that the potential benefits of open source and open access publishing will outweigh 
potential scientific or security threats. Moreover, they offer opportunities to regulate, 
reduce or prevent potential hazards or risks through the improvement of our knowledge of 
how to deal with possible negative impacts and of how to promote global development, 
safety and cooperation.  
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In conclusion, recent advances in bioinformatics toward the development of systems 
biology not only offer new technological opportunities, but also ethical and legal 
challenges.  We may be able to meet the requirements of system biology in a safer and 
integrated world by supporting reliable access to multiple types of data resources, 
programs and applications.  This will allow scientists to study biological phenomena at 
different levels of biological complexity and systemic organisation. This ability will only 
be possible through the implementation of a global and cooperative infrastructure for 
sharing, annotating, analysing and validating methods and findings. Such an infrastructure 
requires the development of standards and protocols to encourage and facilitate controlled 
and shared vocabularies, data formats and usage policies. 
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Nanotechnology and Nanomedicine 
 
J. Anthony Byrne 
 
 
Introduction to Nanotechnology 
There are many different definitions of what nanotechnology is, or indeed, isn’t.  One of 
the most wide ranging and all encompassing definitions was given by the US National 
Science and Technology Council (NSTC: 2000). Accordingly, nanotechnology is: 
“Research and technology development at the atomic, molecular, or macromolecular 
levels, in the length of approximately 1–100 nm range, to provide a fundamental 
understanding of phenomena and materials at the nanoscale, and to create and use 
structures, devices, and systems that have novel properties and functions because of 
their small size. The novel and differentiating properties and functions are developed 
at a critical length scale of matter typically under 100 nm. Nanotechnology research 
and development includes integration of nanoscale structure into larger material 
components, systems, and architectures. Within these larger scale assemblies, the 
control and construction of their structures and component devices remain at the 
nanoscale”. 
The concept of nanotechnology is attributed to Nobel Laureate Richard Feyman due to a 
lecture he gave in 1959 “There is plenty of room at the bottom” which was subsequently 
published in 1960. (Feynman: 1960).  Feynman talked about storage of information on a 
very small scale, writing and reading in atoms, miniaturisation of the computer, building 
tiny machines, building tiny factories and about building electronic circuits with atoms. 
“In the year 2000, when they look back at this age, they will wonder why it was not 
until the year 1960 that anybody began seriously to move in this direction.” (Feynman: 
1960) 
Feyman’s ideas were well ahead of his time and indeed he did not use the term 
‘nanotechnology’ to describe his ideas. The first use of the word 'Nanotechnology' has 
been attributed to Norio Taniguchi in a paper published in 1974 (NSTC: 2000). In 1986 
Eric Drexler published his book “Engines of Creation” in which he describes his ideas of 
molecular nanotechnology used to build miniature machines and devices from the bottom 
up using self-assembly. Many scientists from mainstream disciplines, Biology, Chemistry 
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or Physics will argue of course that they are and have been ‘doing’ nanotechnology for 
years and that it is nothing new. Indeed chemists play with atoms and molecules which are 
sub-nano and molecular biology deals with the understanding and application of biological 
nano-scale components. However, nanotechnology as described by Drexler is not merely 
using nano-components but rather nanotechnology is a coming revolution which will affect 
us in every aspect of our lives. Nature has used nanotechnology for millions it has taken 
millions of years to develop this nano-technology by a process of evolution and natural 
selection.  Nanotechnologists not only wish to mimic how nature does this but we want to 
make nano-devices to do much needed tasks better than and faster than nature can.  
Nanotechnology is an emerging research field which promises to have a wide range of 
interesting applications. By definition it encompasses all technology that aims to create 
nanometer-scaled structures or is able to address or manipulate matter at the nanometer 
level.  
Roughly nanotechnology can be divided in two main parts: top-down and bottom-
up. Development in the top-down methodology was mainly driven from the traditional 
disciplines of (electrical) engineering and physics, while the bottom-up approach, starting 
from single atoms and molecules has more affinity with chemistry and molecular biology. 
Nanotechnology plays at the interface of these two approaches and is therefore inherently 
multidisciplinary. 
Just imagine that in the future we will be able to produce nanoscale machines or 
devices which can manipulate atoms and molecules to build functional structures or 
devices, or to do basically anything we choose?  To be able to do this would indeed create 
a complete technological revolution.  Of course this would affect not only our quality of 
life but there are many ethical and social issues which would need to be addressed. If we 
could build such nano-scale devices they would need to be controlled. What if the 
programming went wrong either by accident or by design. Instead of having technology to 
build and create we could have a weapon of mass destruction which could be under the 
control of extremists or indeed under the control of the device’s themselves. This ethical 
issue has indeed already generated a growing “anti” nanotechnology movement. There are 
an increasing number of nano-fiction books being published which depict the end of the 
World caused by the release of nanotechnology on the earth (and even on the moon). 
However, keeping our nerve we can at least begin to imagine what might be possible. 
Imagine that we could design nanobots which could be injected into the bloodstream (or 
even make their way through the skin). These “nano-meds” are programmed to seek out 
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and repair tumour cells. Or they may be programmed to repair a dysfunctional organ, or 
they may be programmed to turn off the biological clock for cell death, or repair ageing 
tissue. These ideas may be nano-fiction today but already billions of pounds are being 
poured into research towards such objectives. 
 
Nanomedicine 
In Feynman’s famous lecture indeed he mentions the possible use of nanodevices in 
medical applications; 
“A friend of mine (Albert R. Hibbs) suggests a very interesting possibility for 
relatively small machines. He says that, although it is a very wild idea, it would be 
interesting in surgery if you could swallow the surgeon. You put the mechanical 
surgeon inside the blood vessel and it goes into the heart and ``looks’’ around. (Of 
course the information has to be fed out.) It finds out which valve is the faulty one and 
takes a little knife and slices it out. Other small machines might be permanently 
incorporated in the body to assist some inadequately-functioning organ.”  
                                                                                             (Feynman: 1960) 
We have not yet reached the point at which Albert Hibbs’ idea of micro or nano-surgery is 
reality, however, medical applications of nanotechnology are probably those with the most 
exciting potential. Indeed, interest in the medical applications of nanotechnology has led to 
the emergence of a new field called nanomedicine. Nanomedicine has been described as 
the process of diagnosing, treating and preventing disease and traumatic injury, relieving 
pain and preserving and improving human health, using molecular tools and molecular 
knowledge of the human body. In short, nanomedicine is the application of 
nanotechnology to medicine (NSTC: 2000).  
Nanomedicine is a large area and includes nanoparticles that act as biological 
mimetics, ‘nanomachines’, nanofibres and polymeric nanoconstructs as biomaterials (e.g. 
molecular self-assembly and nanofibers of peptides and peptide-amphiphiles for tissue 
engineering, shape-memory polymers as molecular switches, nanoporous membranes), and 
nanoscale fabrication-based devices (e.g. silicon microchips for drug release and 
micromachined hollow needles and two-dimensional needle arrays from single crystal 
silicon), sensors and laboratory diagnostics. Research into the delivery and targeting of 
pharmaceutical, therapeutic, and diagnostic agents using nanosized particles is as the 
forefront of nanomedicine (NSTC: 2000). Freitas (2005) gave a partial taxonomy of 
nanomedicine technologies which was broken down into 18 classes (see Table 1) and 96 
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sub-classes.  This gives us some idea of the potential for applications of nanotechnology in 
medicine. 
 
Table 1 Main classes of nanomedicine technologies (from Freitas: 2005) 
Raw nanomaterials DNA manipulation, 
sequencing, diagnostics 
Molecular medicine 
Nanostructured materials Tools and diagnostics Artificial enzymes and 
enzyme control 
Artificial binding sites Intracellular devices Nanotherapeutics 
Control of surfaces BioMEMS Synthetic biology and early 
nanodevices 
Nanopores Biological research Biotechnology and 
biorobotics 
Cell simulations and cell 
diagnostics 
Drug delivery Nanorobotics 
 
Nanotechnology in drug delivery 
While nanomedicine may be hailed as revolutionary and generate great excitement, most 
working in the fields of drug development and drug delivery will recognize that many 
nanomedicine technologies are not really new. In fact many are already used to treat 
patients. Indeed, since 1990, many drugs referred to as nano-therapeutics have been 
approved as products for clinical use. Most are anticancer drugs i.e. liposomes (e.g. 
DaunoXome), polymer coated liposomes (Doxil, Caelyx), polymeric drugs (Copaxone), 
antibodies (Herceptin, Avastin) and antibody conjugates (Mylotarg), polymer-protein 
conjugates (Oncaspar, Neulasta) and lately, a nanoparticles containing paclitaxel 
(Abraxane). These are nano-scale and commonly multicomponent constructs and can be 
viewed as the first nanomedicines to bring clinical benefits. So these nanomedicines are 
not really new. Many of these concepts e.g. antibody conjugates, liposomes, nanoparticles, 
and polymer-conjugates were developed in the 1970s (NSTC: 2000). However, significant 
funding has been given over to the research and development of nanotechnologies that 
have great potential to contribute to medicine in the short and longer term.  Today, 
nanotechnology and nanoscience approaches to particle design and formulation are 
beginning to expand the market for many drugs and are forming the basis for a very 
- 29 - 
profitable niche within the pharma industry, but some predicted benefits are hyped 
(Moghimi, Hunter and Murray: 2005). 
However, exemplars in the scientific literature which demonstrate the potential and 
the reason for excitement surrounding nanomedicine are overwhelming. The reader is 
referred to the recent reviews by Freitas (2005) and Moghimi, Hunter, and Murray (2005) 
for an overview of the current ‘state of the art’ in nanomedicine and nanotechnology in 
drug delivery. 
Nanomedicine today has branched out in hundreds of different directions, but the 
core concept remains that an ability to structure materials and devices at the molecular 
scale can bring enormous immediate benefits in the research and practice of medicine. It 
has been proposed that miniaturisation of medical tools will provide more accurate, more 
controllable, more versatile, more reliable, cheaper, and faster approaches to enhancing the 
quality of human life (Freitas: 2005). 
 
Risks of Nanotechnology 
Nano-fiction books have generated much concern over the possible risks of 
nanotechnology.  Indeed Prince Charles has been quoted by the Press for raising fears 
about the apocalyptic future brought upon us by nanotechnology. 
“The Prince is said to fear a worst case scenario in which nanotechnology spin-offs 
would annihilate life on earth. 
The Prince is said to be concerned that this could lead to an apocalyptic ‘grey goo’ 
theory in which these miniscule robots would reproduce like viruses, feeding off all 
natural matter and consume the whole planet; leaving behind only a grey goo.” 
       Scotland on Sunday, 27 April 2002 
 
In 2003 the Prince again spoke out about his concerns but this time with a more sober 
approach calling for developments in nanotechnology to be used wisely and appropriately. 
However, the Prince is not the only one to be concerned about the potential risks of 
nanotechnology. Professor David Williams, University of Liverpool, is a member of the 
Scientific Committee on Emerging and Newly Identified Health Risks of the European 
Commission. This committee has presented their report on nanotechnology for adoption 
(NSTC: 2000). Williams recently published an article entitled ‘The risks of 
nanotechnology’ (2005). He cautioned that exploiting the technology for the benefit of 
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mankind may expose the same humans to new health risks. His main concerns were to do 
with the lack of knowledge concerning the toxicology of nanoparticles when inside the 
human body. 
In July 2004 the Royal Society published a report entitled “Nanoscience and 
nanotechnologies: opportunities and uncertainties” Royal Society: 2004).  The report 
illustrates the fact that nanotechnologies offer many benefits both now and in the future but 
that public debate is needed about their development. It also highlights the immediate need 
for research to address uncertainties about the health and environmental effects of 
nanoparticles – one small area of nanotechnologies. It also makes recommendations about 
regulation to control exposure to nanoparticles. 
 
Conclusion 
The concepts of nanotechnology have far reaching implications yet at the moment some of 
these concepts seem like science or nano-fiction to us. However, millions of pounds are 
being poured into research and development of nanotechnology which has the potential to 
change our world forever. There are risks associated with the unknown and as scientists we 
have a responsibility to protect ourselves, those around us, and the world we live in.   
“Although many people believed that nanotechnologies will have an impact across a 
wide range of sectors, a survey of experts in nanotechnologies across the world 
identified hype (misguided promises that nanotechnology can fix everything) as the 
factor most likely to result in a backlash against it.” 
       (Royal Society Report: 2004) 
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Drug design, combinatorial chemistry and drug development  
 
Isabel Rozas 
 
 
Introduction 
There are many drugs in the market and around 6,000 chemical compounds are the bases 
of them. Therefore, one could consider that there is no need for more drugs. However, if 
we look at diseases, we can see that there are still many without a decisive treatment, 
including cancer, Alzheimer’s or Parkinson’s. Besides, new diseases appear as occurred 
with AIDS in the 1980s and Bovine Spongiform Encephalopaty (BSE) in the 1990s and the 
avian flu during 2005. Moreover, there is a problem with uncommon diseases: those that 
affect less than 200,000 people as happens with Tourette’s syndrome or the Paget disease. 
The search for new specialities is therefore totally justified. 
Research in new drugs is the objective of Medicinal Chemistry that deals with the 
design, synthesis and biological evaluation of compounds that can be used in medicine for 
the prevention, treatment or cure of human and animal diseases. Additionally, medicinal 
chemistry includes the study of existing drugs, of their biological properties and of their 
structure-activity relationships. As such, the final objective of medicinal chemistry and, 
therefore, drug design, is to help human kind to overcome the problems associated with 
illnesses. 
Before describing the process of designing a drug, one needs to consider how a 
drug exerts its biological effect. If we consider oral administration, the drug, goes through 
many stages once swallowed. First, it arrives at the stomach and intestines where it will be 
adsorbed in the blood stream. Then, it will be distributed through the blood vessels to reach 
the organ where the drug has to produce its effect. Here it will interact with a 
macromolecule known as the target or receptor. As a consequence of this interaction a 
complex will be formed and this will start a cascade of events that will end in the physical 
change that we perceive as the effect of the drug. 
 
Drug discovery 
In the discovery of a drug we can consider two phases: that of design and synthesis and 
that of development. The first phase consists of three steps: selection of the objective or 
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target, identification of a prototype or lead compound and then its optimisation. And, in the 
development phase we can distinguish between the pre-clinical study, the clinical phases 
and the post-marketing studies.  
The target selection is fundamental in the design and synthesis phase, because this 
is when the biological process and, if possible, the macromolecules (proteins, enzymes, 
nucleic acids) involved in such a process are identified. For example, if we want to find a 
drug to treat depression one of the possible targets will be some macromolecules in the 
brain, for example the alpha2-adrenergic receptors. Some targets are evident, such as 
enzymes involved in metabolic processes that need to be ‘switch off’ by inhibitors, 
(Patrick: 2005) DNA for anticancer agents to avoid the reproduction of the cancer cells, 
(Patrick:2005) or the processes involved in the viral replication cycle for anti-AIDS drugs. 
(De Clerq: 2002). As well, recent advances in the identification of the human genome are 
allowing the identification of new targets. (Harris: 2000). In a second step we will try to 
find a prototype drug or a ‘lead-compound’ which shows a certain activity or affinity 
towards the chosen target. And then, we will optimise this lead-compound - this means, we 
will try to improve its activity, to make it more selective towards the target and to diminish 
its toxicity or unwanted secondary effects. 
How can we find a prototype or ‘lead compound’?  There are two main ways to 
identify a new ‘lead’: rational design and high throughput screening. One of the options of 
rational design is that known as computer assisted drug design or molecular modelling, 
which consists in trying to match the structural requirements of the ligand (drug) with 
those of the target by means of computational techniques such as docking (Meng, Shiochet 
and Kuntz: 1992) and molecular dynamics. (Haile: 1992; Leach: 1996). This methodology 
can be used when both the 3D structure of drug and target are known. Then, with the help 
of certain programs, the structures will be represented in the computer and by using 
different techniques (docking, molecular dynamics) one can make them fit into each other. 
Even when the 3D structures of target and ligand are not known, there are other 
computational techniques that allow the molecular modelling, such as the development of a 
theoretical ‘pharmacophore’ (minimum structure/chemical groups responsible for the 
activity of a drug) (Holtje: 2000), or the modelling of a receptor using ‘homology 
modelling’. (Sali and Blundell: 1993). 
Another very common way to discover lead compounds, totally opposite to rational 
design, would be by ‘serendipity,’ or, the ability of making fortunate discoveries by 
accident and sagacity. Some examples of this are: Penicillin discovered by Fleming who 
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when back at his lab after a summer holiday discovered that mould from one culture 
caused bacteria in its vicinity to undergo lysis. Other known drugs discovered by 
serendipity are the tranquilizer Chlorpromazine or Viagra which was originally developed 
as a drug for heart conditions and it was only later that a certain side effects were noticed. 
The other main method to identify prototype drugs, as mentioned before, is by high 
throughput screening. In 1985, to test 10,000 compounds per year and biological activity 
was considered acceptable. Today, that amount of compounds can be tested in only one 
week or, when using the most sophisticated techniques, those 10,000 compounds can be 
tested in even one hour. To perform these high throughput screenings a large amount of 
compounds are needed and traditional medicinal chemistry by itself cannot generate such 
amounts. Two sources can yield such large amount of compounds: natural products and 
combinatorial chemistry.  
Natural products have always been an important source of ‘lead compounds’ for 
their pharmacological properties. I will only mention some examples that have shown to be 
rather relevant. Epibatidine, is a significant and potent analgesic that is obtained from the 
skin of a frog. (Spande et al: 1992). This compound is 400 times more potent than 
morphine but it is toxic to analgesic doses. Famous taxol is an anticancer agent extracted 
from the pacific yew (Wall and Wani isolated it from the bark of Taxus brevifolia). (Wall 
and Wani: 1995). 
 
Combinatorial chemistry 
Combinatorial chemistry is the simultaneous synthesis of a large number of compounds 
known as a combinatorial library. A library may consist of collections of single compounds 
or groups of mixtures of compounds. These compounds may be synthesised on a solid 
support (where the starting material is bound to a polymer) or in solution. The idea behind 
this methodology is that when searching for a compound with a certain biological activity, 
probability is of importance: the more compounds that are screened, then the higher 
probability of finding a ‘lead compound’. The technique of combinatorial chemistry has 
dramatically changed the way chemists go about searching for lead compounds. The 
essence of combinatorial chemistry is the generation of large numbers of compounds very 
quickly. (Nicolau, Hanko and Hartwig: 2002). The traditional methodology in medicinal 
chemistry involved the preparation, purification and characterization of individual 
compounds; if the whole process is accelerated then better progress can be made. Not too 
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much compound is needed since, in the end, when running a first set of biological assays 
only a few milligrams are required.  
Combinatorial chemistry has its origins in the solid-phase synthesis in parallel first 
developed by Merrifield in 1963 to prepare polypeptides on a polystyrene support. Since 
then, the organic synthesis in solid phase has been mainly used to synthesise peptides, and 
it was not until the 80s when it started to be used to prepare new organic compounds 
searching for new drugs. The method works by attaching the substrate or ‘initial building 
block’ to a solid phase (bead). Then, a reactive (second ‘building block’) will be added, 
reacting with the substrate and allowing purification by simple filtration of the solution 
containing by-products from the solid bead with the two ‘building blocks’ connected. This 
process for making peptides works very well and is now an automated process (Coffen and 
Luithle: 2002). 
In some cases there are disadvantages to solid-phase library generation, for 
example, there are not appropriated solid supports for the compounds we are working with, 
or it is not possible to detach the final compounds from the ‘beads’. A newer approach is to 
use combinatorial synthesis in solution-phase, that is, without attaching the first ‘building 
block’ to the solid support.12 New equipments have been developed allowing for the 
preparation at the same time of many compounds, or ‘parallel synthesis’, in a simple and 
quick manner by only one chemist. These techniques can make use of robotized technology 
in the same way that the peptide synthesis on solid support seen above. These robots 
introduce the solvent, the different reactants after a predetermined time, and control the 
temperature of the whole process. The final objective of their use is to increase productivity 
and precision. (de Witt: 2000). 
A test example of the parallel synthesis in solution phase was performed by 
workers at GlaxoWellcome. They studied a synthesis known as Hantzsch synthesis using 
four ketones and five thioureas to prepare twenty thiazoles with potential anti-
inflammatory properties. The compounds were prepared using a robot. (www.hull.ac.uk). 
Through this combinatorial approach, by using 10 by 10 compounds we would be able to 
obtain 100 compounds but if we use a four component system with 10 different compounds 
for each system we would be able to produce a library of 10,000 compounds. 
Hence, the final objective of combinatorial chemistry is to prepare a large amount 
of new molecules in a quick and inexpensive way. At present, this methodology is not only 
a new synthetic approach, but also has become a sophisticated and automated technology. 
This means that each company can build its own type of libraries. These libraries can be 
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large and unspecific or small and specialized, automated or semi-automated, on solid 
support or in solution, and finally the bio-assay can be performed on the mixtures obtained 
or purify first and then carry out the screening. 
 
Drug development 
All this process until the clinical phase is convergent and all the steps are interrelated and 
aspects such as metabolism or bioavailability are considered from the very beginning of 
the drug design process. Hence, the time between obtaining a prototype and presenting a 
good candidate for clinical phase will be reduced. As we mentioned before, the 
development phase consists in the preclinical studies, then the different clinical phases and 
finally, when the drug reaches the market it continues to be under control by means of 
post-marketing vigilance. 
Pre-clinical studies: include in vitro tests (receptors, cells, isolated tissue) and then 
in vivo tests or animal studies (mice, rat, rabbit, dog). It often requires 4-6 years of clinical 
testing of animal toxicity studies. Research pharmacologists usually develop these studies. 
Clinical phases consist in three different steps: Phase I, II, and III. Phase I: the effects of 
the drug as a function of dosage are established in a small number of healthy volunteers.  
Phase I trials are done to determine whether humans and animals show significantly 
different responses to the drug and to establish the probable limits of the clinical dosage 
range. Much predictable toxicity is detected in this phase. Pharmacokinetic measurements 
of absorption, half-life, and metabolism are often done in phase I. Such studies are usually 
performed in research centres by clinical pharmacologists. Phase II: the drug is studied for 
the first time in patients with the target disease to determine safety and efficacy. A small 
number of patients (10-150) are studied in great detail. A broader range of toxicities may 
be detected in this phase. These trials are usually done in special clinical centres. Phase III: 
the drug is evaluated in much larger number of patients, sometimes thousands. Using 
information gathered in phases II and I, trials are designed to minimize errors caused by 
placebo effects. Phase III studies can be difficult to design and execute and are usually 
expensive, because of the large number of patients involved and the large amounts of data 
that must be collected and analysed. The investigators are usually specialist in the disease 
being treated. Certain toxic effects, especially those caused by sensitisation, may first 
become apparent in this phase III. 
Once approval to market a drug has been obtained the post-marketing phase begins. 
This consists of: monitoring the safety of the new drug under actual conditions of use in 
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large numbers of patients, final release of drug for general prescription use, a vigilant post-
marketing supervision program, and monitoring of adverse reactions reported by 
pharmacists and doctors. Many important drug-induced effects have an incidence of 
1:10,000 or less (therefore, they cannot be detected in Phases I, II or III).  
 
Conclusions 
In sum, between the moment that a ‘lead compound’ is identified and the moment when 
this compound reaches the public domain, a period of around 20 years can pass. With all 
this effort in mind, the ethics behind the whole process is evident.  For many 
pharmaceutical companies, drug discovery has become a very lucrative business. 
Moreover, some unscrupulous governments use legal drugs for non-legal purposes.  
Nevertheless, for academics and researchers, the most important reason behind the design 
of new a drug is to benefit human beings by finding new treatments or improving existing 
treatments to diseases. The challenge remains to find agreement between the different 
actors involved in the drug discovery process. 
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Micro reactors for chemical synthesis. 
 
Paul Watts 
 
 
Abstract 
The miniaturisation of chemical reactors offers many fundamental and practical advantages 
of relevance to the pharmaceutical and fine chemicals industry, which are constantly 
searching for controllable, information rich, high throughput and environmentally friendly 
methods of producing products with a high degree of chemical selectivity. This article 
explores how miniaturisation may revolutionise chemical synthesis. 
 
Introduction 
Until recently, the greatest research effort in the field of miniaturisation has been in 
analytical science with the main aim of this research being to develop so called 
miniaturised Total Analytical System (μ-TAS) (Oosterbroek and van den Berg 2003). 
Alongside the continuing development of μ-TAS, research is underway to establish the 
benefits that micro reactors can bring to the field of synthetic organic chemistry. In 
particular, drug discovery is a very time consuming and expensive process, with one of the 
slowest steps being the synthesis and purification of potential medicinal candidates. Given 
that the success of pharmaceutical companies resides largely on their ability to synthesise 
novel chemical entities and to optimise the production of marketable drugs, the ability to 
more rapidly synthesise and screen novel chemical entities is clearly desirable and this is 
starting to be achieved through the use of micro reactor technology. 
In their simplest form, micro reactors consist of a network of micron-sized channels 
(typically 10-300 μm in diameter) etched into a solid substrate (Figure 1). Glass is a 
popular choice for synthetic applications since it is chemically inert, enables the use of a 
range of visible light detection methods and fabrication techniques are well established 
(Ehrfeld, Hessel and Löwe: 2000; McCreedy: 2000, 396). For solution-based chemistry, 
the channel networks are connected to a series of reservoirs containing chemical reagents 
to form the complete device with overall dimensions of a few cm. In the micro reactor, 
reagents can be brought together in a specific sequence, mixed and allowed to react for a 
specified time in a controlled region of the channel network using electrokinetic or 
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hydrodynamic pumping (Fletcher et.al.: 2002, 4735). For electrokinetically driven systems, 
electrodes are located in the appropriate reservoirs (as illustrated in Figure 1) which allow 
the sequential application of voltages under automated computer control.  In comparison, 
hydrodynamic pumping exploits conventional or micro-scale pumps, notably syringe-type 
pumps to manoeuvre solutions around the channel network.   
 
Figure 1.   A glass micro reactor containing integrated electrodes, which may be used to generate 
electroosmotic flow or used for conductivity measurements. 
 
 
Many chemical reactions have now been demonstrated to show improved reactivity, 
product yield and selectivity when performed in micro reactors compared to those 
generated using conventional laboratory practices (Fletcher et al.: 2002, 4735; Jahnisch et 
al.: 2004, 406; Schwalbe et al.: 2002, 636). Reactions performed in a micro reactor 
invariably generate comparatively pure products in high yield, when compared to the 
equivalent bulk reactions, in much shorter times. One of the immediate and obvious 
applications is therefore in drug and process discovery, where the generation of 
compounds either with different reagents or under variable conditions is an essential factor. 
Performing chemical reactions within a microfluidic system also provides the opportunity 
to perform real time separations. Hence, integration of a micro reactor device via a 
purification/separation step, with one of the many highly sensitive microchannel-based 
biological assay systems would provide a drug discovery tool. This level of integrated 
functionality within one device clearly addresses some of industries’ requirements for 
rapid compound production and screening. Apart from the greatly reduced reaction times 
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demonstrated for the micro reactors, handling times to assay and chemical reagent costs are 
virtually eliminated with this proposed technology. This is shown schematically in Figure 
2.  
 
Figure 2.  Integration of a micro reactor with a biological assay system. 
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In a move to achieve this aim, Garcia-Egido et al. (2002, 170) have recently reported the 
synthesis of a combinatorial library of pyrazoles within micro reactors operated using 
hydrodynamic control. A micro reactor was used to react seven 1,3-dicarbonyl compounds 
with three hydrazine derivatives to produce a library of twenty-one pyrazoles. The 
automated system consisted of an autosampler to introduce the reagents into the chip, a 
HPLC pump to move the reagents through the micro reactor and a dilution system to 
enable a small sample to be diverted to an LC-MS instrument for analysis. The majority of 
the pyrazoles were obtained in 99% conversion, but clearly the chromatography step 
allowed the reaction mixtures to be purified to produce analytically pure compounds. The 
final step would be to couple the output of the chromatography column to a miniaturised 
bioassay system to enable in situ screening to be performed.    
Although the above system is excellent in achieving combinatorial synthesis for the 
desired application, cynics argue that the overall system is hardly miniaturised; the micro 
reactor itself is tiny but the overall system is still composed of large bench top 
instrumentation. This is where EOF-based systems are potentially advantageous as external 
pumps are not necessary and purification could be achieved using on-chip electrophoretic 
separation rather than using large external instrumentation, such as the HPLC described 
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above. In a move to develop an EOF based system, Watts et al. (2002, 5427) have 
demonstrated the first example of multi-step synthesis in a micro reactor where they have 
used the micro reactors in peptide synthesis. The authors demonstrated that peptide bonds 
could be prepared in quantitative conversion in minutes, which represented a significant 
increase in yield compared with the traditional batch syntheses, where only a 50% yield 
was obtained in 24 h. Although the dipeptide bond forming reactions produced the 
dipeptide in 100% conversion based on consumption of the acid moiety, the product was 
still contaminated with residual amine. George et al. (2003, 2886) have reported that the 
dipeptide may be separated from the reaction mixture by incorporating a capillary 
electrophoresis channel into the micro reactor chip itself. Hence this methodology enables 
the synthesis and separation to be efficiently conducted within an integrated micro reactor 
without the need to have large peripheral equipment attached.  
 
Conclusion 
Micro reactor chemistry is currently showing great promise as a novel method on which to 
build new chemical technology and processes. Reactions performed in a micro reactor 
invariably generate relatively pure products in high yield, in comparison to the equivalent 
bulk reactions, in much shorter times and in sufficient quantities to perform full 
instrumental characterisation.  One of the immediate and obvious applications is therefore 
in combinatorial chemistry and drug discovery, where the generation of compounds either 
with different reagents or under variable conditions is an essential factor. An interesting 
twist to the chemistry carried out to date is not just the opportunity to separate reactants 
and products in real time but also the capability to manufacture and use reagents in situ.   
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